Scotland-based ProStrakan Group has unveiled a collaboration deal with U.S. biotechnology group Amgen.
Amgen, one of the world's biggest biotech groups, has been granted an exclusive licence to develop and commercialize certain ProStrakan preclinical compounds for kidney disease.
ProStrakan is striving to create a specialty pharmaceuticals business and
is focusing on areas of unmet medical need. It is looking to buy late-stage
products, with approximately 20 products already on the market.